URSOLIC ACID MORPHOLINE AND DIETHANOLAMINE SALTS
The invention provides diethanolamine and morpholine salts of ursolic acid. Compositions containing the salts, and methods of using the salts are also provided.
1 . An ursolic acid salt selected from ursolic acid diethanolamine salt and ursolic acid morpholine salt.
2 . The ursolic acid salt according to claim 1 , wherein the salt is ursolic acid diethanolamine salt of formula
3 . The ursolic acid salt according to claim 1 , wherein the salt is ursolic acid morpholine salt of formula
4 . A composition comprising a salt according to claim 2 , and a further agent.
5 . The composition according to claim 4 , comprising 25 to 1,500 mg of the salt.
6 . The composition according to claim 4 , comprising 50 to 1,000 mg of the salt.
7 . A composition comprising a salt according to claim 3 , and a further agent.
8 . The composition according to claim 7 , comprising 25 to 1,500 mg of the salt.
9 . The composition according to claim 7 , comprising 50 to 1,000 mg of the salt.
10 . The composition according to claim 4 , wherein the further agent comprises a physiologically acceptable carrier.
11 . The composition according to claim 7 , wherein the further agent comprises a physiologically acceptable carrier.
12 . The composition according to claim 4 , wherein the composition is a pharmaceutical composition, nutraceutical composition, food composition, or dietary supplement.
13 . The composition according to claim 7 , wherein the composition is a pharmaceutical composition, nutraceutical composition, food composition, or dietary supplement.
14 . The composition according to claim 12 , comprising 25 to 1,500 mg of the salt.
15 . The composition according to claim 13 , comprising 25 to 1,500 mg of the salt.
16 . A method for:
(i) increasing skeletal muscle mass;
(ii) treating skeletal muscle atrophy;
(iii) treating sarcopenia;
(iv) treating cachexia;
(v) increasing strength;
(vi) treating weakness;
(vii) increasing exercise capacity;
(viii) treating fatigue;
(ix) promoting muscle growth;
(x) promoting normal muscle function;
(xi) improving muscle function;
(xii) promoting muscle health;
(xiii) promoting healthy aging in muscles;
(xiv) increasing energy expenditure;
(xv) increasing the ratio of skeletal muscle to fat;
(xvi) reducing fat;
(xvii) treating obesity;
(xviii) treating diabetes;
(xix) lowering blood glucose;
(xx) treating pre-diabetes;
(xxi) treating metabolic syndrome;
(xxii) treating insulin resistance;
(xxiii) reducing plasma cholesterol;
(xxiv) treating hypercholesterolemia;
(xxv) reducing plasma triglycerides;
(xxvi) treating hypertriglyceridemia;
(xxvii) promoting healthy metabolism;
(xxviii) promoting metabolic health;
(xxix) treating hypertension;
(xxx) treating atherosclerosis
(xxxi) treating myocardial ischemia;
(xxxii) treating myocardial infarction;
(xxxiii) treating cardiomyopathy;
(xxxiv) treating cardiac arrhythmia;
(xxxv) treating non-alcoholic fatty liver disease (NAFLD);
(xxxvi) treating liver fibrosis;
(xxxvii) treating liver injury;
(xxxviii) treating lung injury;
(xxxix) treating gastric ulcers;
(xl) treating nephropathy;
(xli) promoting bone formation;
(xlii) promoting normal bone structure;
(xliii) promoting bone health;
(xliv) treating osteoporosis;
(xlv) treating cerebral ischemia;
(xlvi) treating cerebral hemorrhage;
(xlvii) treating stroke;
(xlviii) treating traumatic brain injury;
(xlix) treating dementia;
(l) treating Alzheimer's disease;
(li) treating memory loss;
(lii) treating cognitive dysfunction;
(liii) promoting normal cognitive function;
(liv) treating anxiety;
(lv) treating depression;
(lvi) reducing inflammation;
(lvii) treating arthritis;
(lviii) treating skin ulcers;
(lix) treating skin wounds;
(lx) promoting wound healing;
(lxi) treating skin dryness;
(lxii) treating skin roughness;
(lxiii) treating skin scarring;
(lxiv) treating skin wrinkles;
(lxv) reducing unwanted effects of aging;
(lxvi) treating cancer;
(lxvii) reducing tumor growth;
(lxviii) treating tumor metastasis;
(lxix) treating tumor angiogenesis;
(lxx) increasing tumor cell apoptosis;
(lxxi) decreasing protein oxidation;
(lxxii) decreasing lipid oxidation;
(lxxiii) decreasing DNA oxidation;
(lxxiv) decreasing RNA oxidation;
(lxxv) decreasing oxidation of cellular molecules;
(lxxvi) decreasing DNA damage;
(lxxvii) treating bacterial infection;
(lxxviii) reducing bacterial growth;
(lxxix) treating fungal infection;
(lxxx) reducing fungal growth;
(lxxxi) treating viral infection;
(lxxxii) treating protozoal infection;
(lxxxiii) treating nematode infection; or
(lxxxiv) treating a disease state, condition, or disorder mediated by activating transcription factor 4 (ATF4),
in a subject, the method comprising administering to the subject an effective amount of a salt according to claim 1 .
17 . The method according to claim 16 , wherein the salt is ursolic acid morpholine salt.
18 . The method according to claim 16 , comprising administering to the subject a composition that comprises 25 to 1,500 mg of the salt.
19 . The method according to claim 18 , wherein the subject is a human, non-human primate, horse, pig, rabbit, dog, sheep, goat, cow, cat, guinea pig, hamster, ferret, fish, bird, or rodent.
20 . The method according to claim 16 , wherein the subject has not been diagnosed with diabetes or cancer.